tailieunhanh - Searching for novel multimodal treatments in oligometastatic pancreatic cancer

Metastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients with oligometastatic disease could benefit from multimodal treatments connecting chemotherapy and surgical treatment or radiofrequency ablation (RFA) of metastases. | Searching for novel multimodal treatments in oligometastatic pancreatic cancer

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN